Transgender Men show increased monocyte GLUT1 and ROS expression

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00038196

Enrollment

Registered

2025-10-31

Start date

2023-05-30

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pilot study investigating the influence of testosterone in the context of gender-affirming hormone therapy on metabolic activation (GLUT1) and oxidative stress (ROS) in monocytes in transgender men.

Interventions

Group 1: Transgender men pre mastectomy without testosterone hormone therapy Group 2: Transgender men pre mastectomy with testosterone hormone therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - age >18y years - transgender patients recruited from the "Praxis am Medienhafen" - Patients, who are able to unterstand and follow instructions of the staff - written decleration of consent

Exclusion criteria

Exclusion criteria: - age >18 years - missing written decleration of consent

Design outcomes

Primary

Measure	Time frame
Effect of testosterone on GLUT1 and ROS expression on monocytes	—

Secondary

Measure	Time frame
Short- and long-term effects of testosterone on GLUT1 and ROS expression on monocytes	—

Countries

Germany

Contacts

Public ContactLisa Dannenberg

Klinik für Kardiologie, Pneumologie und Angiologie

lisakristina.dannenberg@med.uni-duesseldorf.de0211-81-18800

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026